|
Real-time Estimate
Cboe BZX
11:56:22 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 387.09 USD | -3.25% |
|
-10.03% | -33.51% |
| 07:09am | HEALTH ROUNDS-New blood test matches gold standard for liver disease diagnosis | RE |
| 11-04 | Truist Raises Price Target on Madrigal Pharmaceuticals to $743 From $709, Keeps Buy Rating | MT |
| Market Cap | 9.29B 8.28B 7.58B 6.9B 13B 878B 13.35B 91.01B 36.39B 465B 34.89B 34.14B 1,468B | P/E 2026 * |
-327x | P/E 2027 * | 60x |
|---|---|---|---|---|---|
| Enterprise Value | 8.66B 7.72B 7.06B 6.43B 12.12B 818B 12.44B 84.79B 33.9B 433B 32.5B 31.8B 1,368B | EV / Sales 2026 * |
5.45x | EV / Sales 2027 * | 3.85x |
| Free-Float |
94.2% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MDGL | Delayed | |
CBOE
| MDGL | Real-time | |
|
Tradegate
| YDO1 | Real-time | |
|
Xetra
| YDO1 | Delayed | |
|
Boerse Muenchen
| YDO1 | Real-time | |
|
Deutsche Boerse AG
| YDO1 | Delayed | |
|
Börse Stuttgart
| YDO1 | Delayed | |
|
Borsa Italiana
| 1MDGL | End-of-day quote |
Last Transcript: Madrigal Pharmaceuticals, Inc.
| 1 day | -3.02% | ||
| 1 week | -10.03% | ||
| Current month | -10.03% | ||
| 1 month | -22.01% | ||
| 3 months | -24.13% | ||
| 6 months | -28.26% | ||
| Current year | -33.51% |
| 1 week | 353.54 |  | 482.72 |
| 1 month | 353.54 | | 502.34 |
| Current year | 353.54 | | 598.79 |
| 1 year | 353.54 | | 615 |
| 3 years | 133.98 | | 615 |
| 5 years | 52.33 | | 615 |
| 10 years | 13.09 | | 615 |
| Manager | Title | Age | Since |
|---|---|---|---|
William Sibold
CEO | Chief Executive Officer | 59 | 2023-09-07 |
Mardi Dier
DFI | Director of Finance/CFO | 62 | 2024-03-10 |
David Soergel
CTO | Chief Tech/Sci/R&D Officer | 58 | 2025-04-20 |
| Director | Title | Age | Since |
|---|---|---|---|
Rebecca Taub
BRD | Director/Board Member | 74 | 2016-06-30 |
Richard Levy
BRD | Director/Board Member | 68 | 2016-08-10 |
James Daly
BRD | Director/Board Member | 64 | 2019-06-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/11/26 | Sell | Chief Executive Officer | -5,221 | 0.0226% | ||
| 8/17/26 | Sell | General Counsel | -664 | 0.0029% | ||
| 8/15/26 | Free | Director | 1,725 | 0.0075% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.25% | -10.03% | -20.75% | +162.74% | 9.29B | |
| -4.83% | +2.88% | +55.87% | +69.12% | 69.4B | |
| +0.02% | +1.07% | +10.63% | +76.66% | 57.24B | |
| -1.34% | +2.98% | +24.79% | +100.18% | 57.62B | |
| +2.50% | +1.47% | +28.64% | +36.72% | 43.65B | |
| +5.37% | +9.96% | +22.52% | +107.61% | 44.03B | |
| +7.74% | -0.64% | +209.68% | +782.45% | 38.08B | |
| -1.86% | +11.46% | +26.67% | +61.40% | 36.31B | |
| -2.97% | -9.84% | +88.86% | +76.17% | 32.61B | |
| -2.18% | +5.68% | +36.21% | -0.69% | 25.47B | |
| Average | -0.03% | +1.28% | +48.31% | +147.24% | 41.37B | |
| Weighted average by Cap. | -0.02% | +2.22% | +50.12% | +138.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.59B 1.42B 1.29B 1.18B 2.22B 150B 2.28B 15.55B 6.22B 79.49B 5.96B 5.83B 251B | 2.17B 1.94B 1.77B 1.61B 3.04B 206B 3.13B 21.3B 8.52B 109B 8.16B 7.99B 343B |
| Net income | -35.42M -31.56M -28.87M -26.29M -49.56M -3.35B -50.9M -347M -139M -1.77B -133M -130M -5.59B | 204M 182M 166M 151M 285M 19.26B 293M 2B 798M 10.2B 765M 749M 32.19B |
| Net Debt | -635M -566M -518M -471M -888M -60.01B -912M -6.22B -2.49B -31.78B -2.38B -2.33B -100B | -924M -823M -753M -686M -1.29B -87.32B -1.33B -9.05B -3.62B -46.24B -3.47B -3.39B -146B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-06 | US$386.80 | -3.32% | 502,591 |
| 26-11-05 | US$400.10 | -0.08% | 857,711 |
| 26-11-04 | US$400.43 | +1.04% | 2,313,784 |
| 26-11-03 | US$396.32 | -8.08% | 1,979,229 |
| 26-11-02 | US$431.16 | +0.18% | 495,142 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MDGL Stock
Select your edition
All financial news and data tailored to specific country editions
